•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
TipRanks
50%
rttnews.com
50%
Country
US
Industry
Health Care
Market Cap
Micro Cap
Num. Employees
16
IPO Date
Oct 27, 1993
Country
US
Industry
Health Care
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing programs include SLS-004, SLS-006, and SLS-007.
Seelos Therapeutics’s portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder, amyotrophic lateral sclerosis, or ALS, and spinocerebellar ataxia, or SCA, as well as early-stage programs in Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Related Stocks
Related Stocks
Stocks being mentioned with SEEL
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data